Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

Stopped Genmab has decided to terminate the GEN1057 program due to marginal anti-tumor activity not supporting further development

Conditions

• Advanced Malignant Solid Tumors
• Metastatic Malignant Solid Tumors

Interventions

• DRUG: GEN1057
• DRUG: Premedication

Sponsor

Genmab